Gentian Diagnostics: Second quarter 2024 report

29 Aug 2024 08:00 CEST

Moss, 29 August 2024

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, today announced its results for the second quarter 2024.

Highlights

Sales of NOK 38.3 million in 2Q24, up 12% vs 2Q23 (13% organic growth). Revenue
of NOK 76.8 million in 1H24 up 17% vs 1H23 (16% organic growth).

EBITDA of NOK 6.8 million in 2Q24 versus NOK 3.6 million in 2Q23. EBITDA of NOK
11.6 million in 1H24 versus NOK 3.1 million in 1H23.

Gross margin of 57% positively influenced by favourable product mix and
finalisation of integration with Getica AB, which was acquired in July 2023

Sales of fCAL® turbo increased 26% in 2Q24 compared to 2Q23 and by 33% in 1H24
vs 1H23

Sales of Cystatin C were NOK 13.3 million during 2Q24 and NOK 28.2 million in
1H24 recording growth of 8% and 9% respectively. Weakened order patterns from
China is expected to continue throughout this year.

Major milestone achieved with the successful completion of NT-proBNP
optimisation phase



Webcast

The company will present the results today at 10.00 am, followed by a Q&A
session. Join the webcast and submit questions via the following link:

https://attendee.gotowebinar.com/register/759916907804036701

The webcast will be available on the company website after the presentation.

IR contact:

Njaal Kind, CEO
njaal.kind@gentian.no
+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Ole Sørlie, Business
Controller at Gentian Diagnostics ASA, on 29 August 2024 at 08:00 CET.


About Gentian
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Gentian’s expertise and focus lies within homogenous
immunoassays, specifically infections, inflammations, kidney failures and
congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is
headquartered in Moss, Norway, serving the global human and veterinary
diagnostics markets through sales and representative offices in Sweden, USA, and
China. For more information, please visit www.gentian.com.

More information:
Access the news on Oslo Bors NewsWeb site

626512_GDASA Q2 24 presentation.pdf
626512_GDASA Interim report 2Q 2024.pdf